Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Diverse cross-resistance phenotype to ET-743 (Yondelis®;Trabectedin) and PM00104 (Zalypsis®) in multi-drug resistant cell lines selected in vitro using paclitaxel, doxorubicin or cisplatin

Diverse cross-resistance phenotype to ET-743 (Yondelis®;Trabectedin) and PM00104 (Zalypsis®) in multi-drug resistant cell lines selected in vitro using paclitaxel, doxorubicin or cisplatin. Cancer Chemother Pharmacol. 2009; 63(6):1121-9.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.